Plain-English translation of NCT02269592 on ClinicalTrials.gov ↗ ·
Researchers at Dana-Farber Cancer Institute are studying how blood cancers and pre-cancerous blood conditions develop and progress. They will analyze tissue samples and blood from patients with conditions like MGUS, smoldering myeloma, early myelodysplastic syndromes, and early-stage lymphomas to understand the molecular changes that happen as these diseases advance. This knowledge could help doctors predict which patients will progress to active cancer and develop better treatments.
Many people have pre-cancerous changes in their blood that may never become active cancer, while others progress to serious disease. Doctors currently cannot reliably predict who will progress and who will remain stable. By studying the molecular patterns in these early conditions, researchers hope to identify warning signs and eventually offer better monitoring and treatment options.
You likely qualify if…
You likely don't qualify if…
Your participation will mostly use samples and medical information already collected during your regular care—no extra biopsies or invasive procedures are needed. Researchers will ask for your permission to use these existing samples and may request one small additional sample (a few teaspoons of blood, a gentle mouth swab, or a small skin sample) to study your normal cells for comparison. You will also be asked to attend regular follow-up visits so researchers can track whether your condition stays stable or progresses, and they will link what they find in your samples with your clinical information over time.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States